Angiotensin-converting enzyme 2 (ACE2)
Angiotensin I converting enzyme 2 (ACE2) is a membrane-associated protein best known as a key regulator of the renin–angiotensin system and as the cellular receptor used by SARS-CoV-2 for entry into host cells.
Angiotensin I converting enzyme 2 (ACE2) is a membrane-associated protein best known as a key regulator of the renin–angiotensin system and as the cellular receptor used by SARS-CoV-2 for entry into host cells. In normal physiology, ACE2 counterbalances angiotensin-converting enzyme activity by processing angiotensin peptides, thereby contributing to vascular, renal, and inflammatory homeostasis. Because of this dual role in human biology and viral attachment, ACE2 has become an important target in cardiovascular, renal, and infectious disease research.
Structurally, ACE2 is of major interest because its extracellular domain directly engages the receptor-binding domain of the SARS-CoV-2 spike protein. Variants and mutations in the viral spike can alter this interaction, affecting infectivity and immune escape. ACE2 is also studied in disease-associated expression analyses, including kidney disorders, where altered ACE2 expression may reflect changes in tissue injury, inflammation, or immune infiltration.
Where the papers sit
10 papers from the last 6 months study Angiotensin-converting enzyme 2 (ACE2) directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 2 observational · 6 human data · 2 preclinical
Themes 3 themes · 1 new direction
-
SARS-CoV-2 Entry Therapies
ACE2-targeted antiviral design is moving from computational discovery toward engineered entry blockade and intracellular delivery. Candidate strategies include virtual screening, IL-27 gene therapy, and ACE2-PNA conjugates that use viral endocytosis. Nanoswitch screening and protein-lipid virus-like particles broaden the toolkit for finding or presenting antiviral agents. Efficacy remains exploratory, with SARS-CoV-2 entry and antiviral activity as recurring endpoints.
5 papers · 50%
-
ACE2 in Cardiorenal Pregnancy
ACE2 is being linked to cardiorenal and reproductive risk through circulating biomarkers and tissue-level regulation. In pregnancy, cardiovascular protein profiles are being evaluated for later preeclampsia and small-for-gestational-age outcomes. Kidney transplant work connects proteinuria with cardiac biomarker levels, while high-fat diet models implicate ACE2 downregulation in adverse cardiovascular and reproductive effects. The shared question is whether ACE2-related signals can improve risk stratification or explain disease mechanisms.
3 papers · 30%
-
Antibody Escape in SARS-CoV-2
Antibody escape mapping is shifting toward proactive prediction of SARS-CoV-2 variant resistance. Deep mutational scanning and machine learning are paired with iterative experiments to identify receptor-binding-domain changes that weaken antibody binding. The goal is to anticipate trajectories of emerging variants and preserve neutralization through antibody design or combination therapy. Wild-type comparisons remain important, but the durability of predictions across circulating variants is still open.
2 papers · 20%
ACE2 is repurposed as a virus-triggered intracellular delivery conduit rather than only as a viral-entry receptor or extracellular neutralization target
The SARS-CoV-2 ACE2-PNA conjugate study used ACE2-Fc to carry peptide nucleic acids targeting the viral ORF1ab region into infected cells through virus-mediated endocytosis, while retaining ACE2’s extracellular neutralizing activity; thus, ACE2 becomes a receptor-drug conjugate that delivers an antiviral payload intracellularly, adding a delivery role not represented by the other studies’ receptor-blocking, interaction-modeling, protective-axis, or biomarker uses 42545604Aug.
Papers
The 10 papers from the last 6 months that study Angiotensin-converting enzyme 2 (ACE2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
SARS-CoV-2 Entry Therapies (5)
- Discovering molecular modulators with nanoswitch screening. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986965
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
- Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry. Molecular biology reports · 11 Jul 2026 PMID 42435246
- Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem · 22 May 2026 PMID 42174382
- Bottom-Up Creation of Virus-like Particles via Post-Insertion of Protein-Lipid Conjugates. ACS synthetic biology · 20 May 2026 PMID 42160665
ACE2 in Cardiorenal Pregnancy (3)
- Correlation between proteinuria and cardiac biomarker levels in kidney transplant recipients. Renal failure · 10 Nov 2026 PMID 43009172
- ACE2 downregulation contributes to adverse cardiovascular and reproductive outcomes in female mice on high-fat diet. American journal of physiology. Heart and circulatory physiology · 8 Sept 2026 PMID 42710476
- A case-control study of mid-pregnancy circulating cardiovascular proteins in women with subsequent preeclampsia and small for gestational age births. Scientific reports · 6 Jul 2026 PMID 42409921
Antibody Escape in SARS-CoV-2 (2)
- Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
- Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern. PLoS computational biology · 17 Jun 2026 PMID 42308256
By study type
Observational studies and case reports (2)
- Correlation between proteinuria and cardiac biomarker levels in kidney transplant recipients. Renal failure · 10 Nov 2026 PMID 43009172
- A case-control study of mid-pregnancy circulating cardiovascular proteins in women with subsequent preeclampsia and small for gestational age births. Scientific reports · 6 Jul 2026 PMID 42409921
Human data, design not indexed (6)
- Discovering molecular modulators with nanoswitch screening. Science (New York, N.Y.) · 5 Nov 2026 PMID 42986965
- Evaluating SARS-CoV-2 antibody resilience via prediction and design of escape viral variants. Cell systems · 17 Jul 2026 PMID 42468530
- Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry. Molecular biology reports · 11 Jul 2026 PMID 42435246
- Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern. PLoS computational biology · 17 Jun 2026 PMID 42308256
- Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem · 22 May 2026 PMID 42174382
- Bottom-Up Creation of Virus-like Particles via Post-Insertion of Protein-Lipid Conjugates. ACS synthetic biology · 20 May 2026 PMID 42160665
Preclinical: animal, cell and lab studies (2)
- ACE2 downregulation contributes to adverse cardiovascular and reproductive outcomes in female mice on high-fat diet. American journal of physiology. Heart and circulatory physiology · 8 Sept 2026 PMID 42710476
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-18. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.